Marc Buyse

Chief Scientific Officer

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Research Cancer Research professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Marc Buyse is the Chief Scientific Officer at IDDI in the United States. His research areas include clinical trial design, noninferiority trials in oncology, and patient-centric outcomes. He has published extensively on topics such as treatment regimens, patient-reported outcomes, and survival metrics in metastatic cancer. His recent work emphasizes improving clinical trial methodologies and the importance of treatment benefit assessment in immuno-oncology.

Articles (9)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Thierry André

Sorbonne Université

FRANCE

View details

Tomasz Burzykowski

Medical University of Białystok

POLAND

View details

Ashley M Hopkins

AUSTRALIA

View details

Timothy Stanley Maughan

Professor of Clinical Oncology, CRUK/MRC Oxford Institute for Radiation Oncology

University of Oxford

UNITED KINGDOM

View details

Cathy Eng

Vanderbilt University Medical Center

UNITED STATES

View details

PIERFRANCO CONTE

Professore di 1^ fascia

University of Padova

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Marc Buyse

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

Noninferiority trials in oncology: need for improvement, or a paradigm shift?

From non-inferiority to superiority: the shift towards patient-centric outcomes

Design of a clinical trial using generalized pairwise comparisons to test a less intensive treatment regimen

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis

Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

Central statistical monitoring of investigator-led clinical trials in oncology

Assessing Treatment Benefit in Immuno-oncology

Collaborators (6)

Thierry André

Tomasz Burzykowski

Ashley M Hopkins

Timothy Stanley Maughan

Cathy Eng

PIERFRANCO CONTE

Make your next move.